FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:580-592 February 8, 2007 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

ABSTRACT

Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis.

Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 monoclonal antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 monoclonal antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 monoclonal antibody at week 20.

Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 monoclonal antibody, in 59% of those who received 90 mg, in 67% of those who received four weekly 45-mg doses, and in 81% of those who received four weekly 90-mg doses, as compared with 2% of those who received placebo (P<0.001 for each comparison), and there was at least 90% improvement in 23%, 30%, 44%, and 52%, respectively, of patients who received the monoclonal antibody as compared with 2% of patients who received placebo (P<0.001 for each comparison). Adverse events occurred in 79% of patients treated with the interleukin-12/23 monoclonal antibody as compared with 72% of patients in the placebo group (P=0.19). Serious adverse events occurred in 4% of patients who received the monoclonal antibody and in 1% of those who received placebo (P=0.69).

Conclusions This study demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and provides further evidence of a role of the interleukin-12/23 p40 cytokines in the pathophysiology of psoriasis. Larger studies are needed to determine whether serious adverse events might limit the clinical usefulness of this new therapeutic target. (ClinicalTrials.gov number, NCT00320216 [ClinicalTrials.gov] .)

Source Information

From the University of Utah, Salt Lake City (G.G.K.); Dalhousie University, Halifax, NS, Canada (R.G.L.); Saint Louis University, St. Louis (C.L.); Centocor, Malvern, PA (N.Y., C.G., Y.W., L.T.D.); and Mount Sinai School of Medicine, New York (M.L.).

Address reprint requests to Dr. Krueger at 30 N. 1900 East, Suite 4B-454, Salt Lake City, UT 84132, or to gerald.krueger{at}derm.med.utah.edu.

Full Text of this Article

This article has been cited by other articles:

• Hillyer, P., Larche, M. J., Bowman, E. P., McClanahan, T. K., de Waal Malefyt, R., Schewitz, L. P., Giddins, G., Feldmann, M., Kastelein, R. A., Brennan, F. M. (2009). Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford) 48: 1581-1589 [Abstract] [Full Text]  
• Abraham, C., Cho, J. H. (2009). Inflammatory Bowel Disease. NEJM 361: 2066-2078 [Full Text]  
• Gillooly, K. M., Pattoli, M. A., Taylor, T. L., Chen, L., Cheng, L., Gregor, K. R., Whitney, G. S., Susulic, V., Watterson, S. H., Kempson, J., Pitts, W. J., Booth-Lute, H., Yang, G., Davies, P., Kukral, D. W., Strnad, J., McIntyre, K. W., Darienzo, C. J., Salter-Cid, L., Yang, Z., Wang-Iverson, D. B., Burke, J. R. (2009). Periodic, Partial Inhibition of I{kappa}B Kinase {beta}-Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis. J. Pharmacol. Exp. Ther. 331: 349-360 [Abstract] [Full Text]  
• Scanlon, J. V, Exter, B. P, Steinberg, M., Jarvis, C. I (2009). Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis. The Annals of Pharmacotherapy 43: 1456-1465 [Abstract] [Full Text]  
• Katsifis, G. E., Rekka, S., Moutsopoulos, N. M., Pillemer, S., Wahl, S. M. (2009). Systemic and Local Interleukin-17 and Linked Cytokines Associated with Sjogren's Syndrome Immunopathogenesis. Am. J. Pathol. 175: 1167-1177 [Abstract] [Full Text]  
• Miossec, P., Korn, T., Kuchroo, V. K. (2009). Interleukin-17 and Type 17 Helper T Cells. NEJM 361: 888-898 [Full Text]  
• LOFFREDO, S., AYALA, F., MARONE, G., DELFINO, G., STRANGES, S., MARONE, G. (2009). Immunopathogenesis of Psoriasis and Pharmacological Perspectives. The Journal of Rheumatology Supplement 83: 9-11 [Abstract] [Full Text]  
• PINCELLI, C., LOTTI, R. (2009). What's New in Laboratory Research?. The Journal of Rheumatology Supplement 83: 17-18 [Abstract] [Full Text]  
• Chang, B. Y., Zhao, F., He, X., Ren, H., Braselmann, S., Taylor, V., Wicks, J., Payan, D. G., Grossbard, E. B., Pine, P. R., Bullard, D. C. (2009). JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice. J. Immunol. 183: 2183-2192 [Abstract] [Full Text]  
• van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., Lubberts, E. (2009). Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis. J. Immunol. 182: 5836-5845 [Abstract] [Full Text]  
• Andre, S., Tough, D. F., Lacroix-Desmazes, S., Kaveri, S. V., Bayry, J. (2009). Surveillance of Antigen-Presenting Cells by CD4+CD25+ Regulatory T Cells in Autoimmunity: Immunopathogenesis and Therapeutic Implications. Am. J. Pathol. 174: 1575-1587 [Abstract] [Full Text]  
• Nair, R. P., Ding, J., Duffin, K. C., Helms, C., Voorhees, J. J., Krueger, G. G., Bowcock, A. M., Abecasis, G. R., Elder, J. T. (2009). Psoriasis Bench to Bedside: Genetics Meets Immunology. Arch Dermatol 145: 462-464 [Full Text]  
• Wolfram, J. A., Diaconu, D., Hatala, D. A., Rastegar, J., Knutsen, D. A., Lowther, A., Askew, D., Gilliam, A. C., McCormick, T. S., Ward, N. L. (2009). Keratinocyte but Not Endothelial Cell-Specific Overexpression of Tie2 Leads to the Development of Psoriasis. Am. J. Pathol. 174: 1443-1458 [Abstract] [Full Text]  
• Zhu, Y., Hu, C., Lu, M., Liao, S., Marini, J. C., Yohrling, J., Yeilding, N., Davis, H. M., Zhou, H. (2009). Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis. J Clin Pharmacol 49: 162-175 [Abstract] [Full Text]  
• RAHMAN, P., INMAN, R. D., MAKSYMOWYCH, W. P., REEVE, J. P., PEDDLE, L., GLADMAN, D. D. (2009). Association of Interleukin 23 Receptor Variants with Psoriatic Arthritis. The Journal of Rheumatology 36: 137-140 [Abstract] [Full Text]  
• Prodanovich, S., Shelling, M. L., Federman, D. G., Kirsner, R. S. (2008). Cytokine Milieu in Psoriasis and Cardiovascular Disease May Explain the Epidemiological Findings Relating These 2 Diseases. Arch Dermatol 144: 1518-1519 [Full Text]  
• Kryczek, I., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Aphale, A., Vatan, L., Szeliga, W., Wang, Y., Liu, Y., Welling, T. H., Elder, J. T., Zou, W. (2008). Induction of IL-17+ T Cell Trafficking and Development by IFN-{gamma}: Mechanism and Pathological Relevance in Psoriasis. J. Immunol. 181: 4733-4741 [Abstract] [Full Text]  
• Kimball, A. B., Gordon, K. B., Langley, R. G., Menter, A., Chartash, E. K., Valdes, J., for the ABT-874 Psoriasis Study Investigators, (2008). Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled, Phase 2 Trial. Arch Dermatol 144: 200-207 [Abstract] [Full Text]  
• Gaston, J. S. H. (2008). Cytokines in arthritis the 'big numbers' move centre stage. Rheumatology (Oxford) 47: 8-12 [Abstract] [Full Text]  
• Arakura, F., Hida, S., Ichikawa, E., Yajima, C., Nakajima, S., Saida, T., Taki, S. (2007). Genetic Control Directed toward Spontaneous IFN-{alpha}/IFN-beta Responses and Downstream IFN-{gamma} Expression Influences the Pathogenesis of a Murine Psoriasis-Like Skin Disease. J. Immunol. 179: 3249-3257 [Abstract] [Full Text]  
• Okamoto, H., Momohara, S., Krueger, G. G., Langley, R. G., Yeilding, N. (2007). Interleukin-12/23 Monoclonal Antibody for Psoriasis. NEJM 356: 2003-2003 [Full Text]  
• (2007). Biologics for Psoriasis: The Second Generation. Journal Watch Dermatology 2007: 1-1 [Full Text]